Everand Logo

Welcome to Everand!

  • STAT

    For the first time, clinical trial results show Ebola drugs improve survival rates

    The NIH and WHO say that clinical trial data show experimental drugs improved survival rates in people who contracted Ebola.
    by Helen Branswell Aug 12, 2019 4 minutes
    Health workers wearing protective gear check on a mother of four whose husband died of Ebola at a treatment center in Beni, Congo.

    A historic clinical trial has shown that two therapies made from Ebola antibodies appear to be improving survival rates among people who receive them, health officials announced Monday. The announcement marks the first time a clinical trial has successfully shown that an Ebola therapy improves survival in people who have been infected.

    Two other therapies used in the clinical trial performed less well and will be discontinued.

    The therapies that have improved survival rates are REGN-EB3, a cocktail of three monoclonal Ebola antibodies made by Regeneron Pharmaceuticals, and mAb114, a single monoclonal antibody developed by the National Institute of Allergy

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
    The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
    New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

    Related Books & Audiobooks